HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hill Top

This article was originally published in The Rose Sheet

Executive Summary

Acquisition of U.K.-based Globe Crown provides consumer products clinical testing company a presence in European market. Globe Crown provides safety and efficacy testing, claims substantiation and in vitro testing. The acquisition adds Globe Crown's five research facilities - five in the U.S., two in the U.K. and one in Canada - to Hill Top's 29 centers. The new U.K. unit is called Hill Top-Globe Crown and is headed by Globe Crown founder Tony Barlow, PhD. Hill Top (Cincinnati) provides testing capabilities in the personal care, cosmetics, oral care, skin care, pharmaceutical and medical device fields. Revenues for the consumer products arm are growing at a rate of 15% annually, and Hill Top's yearly consolidated revenues total more than $41 mil. The company hopes to expand into France and Germany through additional acquisitions and internal growth
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS005992

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel